EGFR/HDAC-IN-1

EGFR/HDAC-IN-1 (Compound 22c2) is a potent dual inhibitor of epidermal growth factor receptor (EGFR) and histone deacetylase (HDAC), exhibiting IC50 values of 4.81 nM for EGFR, 119.4 nM for HDAC1, and 354.8 nM for HDAC3. It disrupts the EGFR signaling pathway and alters histone acetylation status, thereby inhibiting tumor cell proliferation. EGFR/HDAC-IN-1 is a promising candidate for research in non-small cell lung cancer (NSCLC) .